Scholar Rock Holding Corp
2QK
Company Profile
Business description
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Contact
301 Binney Street
3rd Floor
CambridgeMA02142
USAT: +1 857 259-3860
E: chu@scholarrock.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
196
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,738.30 | 118.30 | -1.34% |
| CAC 40 | 7,967.93 | 151.09 | -1.86% |
| DAX 40 | 23,180.53 | 409.99 | -1.74% |
| Dow JONES (US) | 46,091.74 | 498.50 | -1.07% |
| FTSE 100 | 9,552.30 | 123.13 | -1.27% |
| HKSE | 25,930.03 | 454.25 | -1.72% |
| NASDAQ | 22,432.85 | 275.23 | -1.21% |
| Nikkei 225 | 48,702.98 | 1,620.93 | -3.22% |
| NZX 50 Index | 13,359.53 | 16.71 | 0.13% |
| S&P 500 | 6,617.32 | 55.09 | -0.83% |
| S&P/ASX 200 | 8,469.10 | 109.70 | -1.28% |
| SSE Composite Index | 3,939.81 | 32.22 | -0.81% |